| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $142,091 ) |
| | 2025 | 2025 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R21AI182639 | Investigating Plasmodium vaccination in 'dirty' mice | 000 | 1 | NIH | 11/13/2024 | $205,125 |
| | 2025 | 2025 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01DK134482 | Shared decision making for kidney transplant candidates to plan for an organ offer decision | 000 | 3 | NIH | 11/27/2024 | $244,570 |
| | 2025 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01AI140303 | Gut Microbiota and Effect on Immune Suppressants in Transplantation | 000 | 5 | NIH | 12/4/2024 | -$307,604 |
| | 2025 | 2023 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01DA053608 | An evaluation of Beta-nicotyrine as a potential contributor to the abuse liability of e-cigarettes | 000 | 3 | NIH | 12/9/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $4,977,314 ) |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | UG1DA040316 | NorthStar Node of the Clinical Trials Network | 004 | 10 | NIH | 7/16/2024 | $0 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01DK135730 | Virtual coaching for potential kidney transplant candidates and their social support networks | 000 | 2 | NIH | 1/29/2024 | $237,683 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01DK135730 | Virtual coaching for potential kidney transplant candidates and their social support networks | 001 | 2 | NIH | 5/6/2024 | $15,845 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01DK140270 | A clinical decision support tool to understand the survival benefit of kidney transplantation in candidates with a history of cancer | 000 | 1 | NIH | 9/4/2024 | $348,657 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R21AG081689 | Plasma-Based Neuronal Insulin Signaling Exosomes as a Biomarker for Cognitive Impairment in Diabetes | 000 | 1 | NIH | 8/22/2024 | $212,816 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01DK134482 | Shared decision making for kidney transplant candidates to plan for an organ offer decision | 001 | 2 | NIH | 5/2/2024 | $16,389 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01DK134482 | Shared decision making for kidney transplant candidates to plan for an organ offer decision | 000 | 2 | NIH | 11/21/2023 | $245,833 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01AI185750 | Enhancing T and B cell responses to Plasmodium infection and vaccination via IL-15 | 001 | 1 | NIH | 9/3/2024 | $49,935 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01AI185750 | Enhancing T and B cell responses to Plasmodium infection and vaccination via IL-15 | 000 | 1 | NIH | 6/20/2024 | $556,832 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01AG084437 | Vaccine immunity and inflammation in the aging person living with HIV | 000 | 1 | NIH | 7/3/2024 | $677,777 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01DK137159 | A Learning Health System to increase organ donation and equity in populations experiencing health disparities | 000 | 2 | NIH | 7/1/2024 | $172,779 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01HS028829 | New Patient-centered Metric for Transplant Center Report Cards | 001 | 3 | AHRQ | 7/15/2024 | $391,155 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | UH3DE029973 | Effectiveness of Nicotine Replacement Therapy Sampling in Dental Practices | 001 | 5 | NIH | 8/1/2024 | $578,705 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | RF1AG079397 | Sex-specific risk factors and trajectories of blood biomarkers for Alzheimer's disease and related dementias | 000 | 1 | NIH | 5/16/2024 | $387,497 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01HL160437 | Clinical and immunologic factors underlying heart failure with preserved ejection fraction among persons with HIV in South Africa | 000 | 4 | NIH | 8/19/2024 | $513,760 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01DA048899 | Comparative neurobehavioral pharmacology of combusted and non-combusted tobacco products | 000 | 5 | NIH | 5/16/2024 | $633,574 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | K23MH124466 | Understanding STI and HIV prevention adherence among Kenyan women | 000 | 6 | NIH | 7/17/2024 | $187,812 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R13HS029436 | Research Conference to develop a national healthcare workforce wellness research agenda for AHRQ in the Learning Health System (LHS) program | 000 | 2 | AHRQ | 8/2/2024 | $48,123 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01AI140303 | Gut Microbiota and Effect on Immune Suppressants in Transplantation | 001 | 5 | NIH | 5/28/2024 | $65,738 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01AI140303 | Gut Microbiota and Effect on Immune Suppressants in Transplantation | 000 | 5 | NIH | 1/16/2024 | $591,663 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | U01NS095926 | Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial - CCC | 003 | 5 | NIH | 7/9/2024 | $0 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | U01NS095926 | Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial - CCC | 001 | 5 | NIH | 6/13/2024 | $626,120 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | UG1DA040316 | NorthStar Node of the Clinical Trials Network | 005 | 10 | NIH | 9/10/2024 | $0 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | UG1DA040316 | NorthStar Node of the Clinical Trials Network | 003 | 10 | NIH | 6/27/2024 | $0 |
| | 2024 | 2024 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | UG1DA040316 | NorthStar Node of the Clinical Trials Network | 002 | 10 | NIH | 4/24/2024 | $1 |
| | 2024 | 2023 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01HS028829 | New Patient-centered Metric for Transplant Center Report Cards | 000 | 2 | AHRQ | 12/14/2023 | $0 |
| | 2024 | 2023 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | UH3DE029973 | Effectiveness of Nicotine Replacement Therapy Sampling in Dental Practices | 000 | 4 | NIH | 6/1/2024 | $0 |
| | 2024 | 2023 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01DA053608 | An evaluation of Beta-nicotyrine as a potential contributor to the abuse liability of e-cigarettes | 000 | 3 | NIH | 8/29/2024 | $0 |
| | 2024 | 2023 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | U19AG062682 | ASPirin in Reducing Events in the Elderly - eXTension | 000 | 5 | NIH | 10/26/2023 | $0 |
| | 2024 | 2023 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | U19AG062682 | ASPirin in Reducing Events in the Elderly - eXTension | 000 | 5 | NIH | 10/26/2023 | $0 |
| | 2024 | 2023 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | UG1DA040316 | NorthStar Node of the Clinical Trials Network | 001 | 9 | NIH | 11/7/2023 | $0 |
| | 2024 | 2023 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | UG1DA040316 | NorthStar Node of the Clinical Trials Network | 001 | 9 | NIH | 11/7/2023 | $0 |
| | 2024 | 2022 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | K01AI130409 | Genetic Variants Associated with Tacrolimus Metabolism in Kidney Transplant Recipients | 000 | 5 | NIH | 8/1/2024 | $0 |
| | 2024 | 2022 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | U01NS095926 | Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial - CCC | 002 | 5 | NIH | 7/9/2024 | $0 |
| | 2024 | 2022 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | U01NS095926 | Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial - CCC | 000 | 5 | NIH | 12/28/2023 | $0 |
| | 2024 | 2022 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R01HL136327 | Secondary Prevention Following Acute Coronary Syndrome Using Integrated Smoking Cessation and Mood Management | 000 | 5 | NIH | 6/25/2024 | $0 |
| | 2024 | 2022 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | R34DA046078 | Implementation of Cessation Treatment in Community Based Mental Health Centers | 000 | 3 | NIH | 4/2/2024 | $0 |
| | 2024 | 2021 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | K24DK085153 | Prevalence and Impact of Frailty among Dialysis Patients | 001 | 11 | NIH | 1/8/2024 | -$149,045 |
| | 2024 | 2020 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | K24DK085153 | Prevalence and Impact of Frailty among Dialysis Patients | 000 | 10 | NIH | 1/8/2024 | -$20,250 |
| | 2024 | 2019 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | UG1DA040316 | NorthStar Node of the Clinical Trials Network | 000 | 5 | NIH | 10/1/2023 | -$332,977 |
| | 2024 | 2019 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | U01DK123816 | The Hemodialysis Opioid Prescription Effort Consortium | 000 | 1 | NIH | 9/23/2024 | -$1,045,532 |
| | 2024 | 2018 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | RF1AG058729 | The Natural History of Cognitive Decline in Chronic Kidney Disease: Renal, Vascular and Alzheimer's Disease Contributions | 000 | 1 | NIH | 10/1/2023 | -$33,577 |
|
| Issue Date FY: 2023 ( Subtotal = $18,224,295 ) (Continued on the next page) |
| | 2023 | 2023 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 701 PARK AVE | MINNEAPOLIS | MN | 55415-1623 | HENNEPIN | USA | UG1DA040316 | NorthStar Node of the Clinical Trials Network | 005 | 9 | NIH | 7/10/2023 | $0 |
|
